KALARIS THERAPEUTICS, INC. Gain (Loss) on Termination of Lease
KALARIS THERAPEUTICS, INC. (KLRS) reported Gain (Loss) on Termination of Lease of $5.58 million for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-13.
Discontinued › Income Statement › Other Income
us-gaap:GainLossOnTerminationOfLease · last filed 2024-05-13
- KALARIS THERAPEUTICS, INC. gain (loss) on termination of lease for the quarter ending 2024-03-31 was $5.58M.
| Period end | Gain (Loss) on Termination of Lease 3 month |
|---|---|
| 2024-03-31 | $5.58M 10-Q · filed 2024-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |